共 173 条
[1]
Resnikoff S(2004)Global data on visual impairment in the year 2002 Bull World Health Organ 82 844-851
[2]
Pascolini D(2004)Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 477-485
[3]
Etya’ale D(2009)Inflammation and the pathogenesis of age-related macular degeneration Expert Opin Ther Targets 13 641-651
[4]
Kocur I(2008)Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial Br J Ophthalmol 92 1606-1611
[5]
Pararajasegaram R(2006)Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration Ophthalmology 113 1508-1521
[6]
Pokharel GP(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[7]
Mariotti SP(2009)Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 57-65
[8]
Congdon N(2014)Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 193-201
[9]
O’Colmain B(2013)Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration Am J Ophthalmol 156 29-35
[10]
Klaver CC(2013)Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab Br J Ophthalmol 97 1032-1035